-
Signature
-
/s/ Keyur Parekh, as Authorized Signatory
-
Issuer symbol
-
IMVT
-
Transactions as of
-
12 Dec 2025
-
Net transactions value
-
+$349,999,986
-
Form type
-
4
-
Filing time
-
12 Dec 2025, 17:17:21 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Roivant Sciences Ltd. |
Director, 10%+ Owner |
7TH FLOOR, 50 BROADWAY, LONDON, UNITED KINGDOM |
/s/ Keyur Parekh, as Authorized Signatory |
12 Dec 2025 |
0001635088 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
IMVT |
Common Stock, $0.0001 par value per share |
Purchase |
$349,999,986 |
+16,666,666 |
+17% |
$21.00 |
113,317,007 |
12 Dec 2025 |
Direct |
|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Remarks:
The Reporting Person is deemed to be a "director by deputization" of the Issuer for purposes of Section 16 of the Securities Exchange Act of 1934 by virtue of the fact that Frank M. Torti, M.D. (who serves as President & Vant Chair of Roivant Sciences, Inc. ("RSI"), a subsidiary of the Reporting Person), Eric Venker, M.D., Pharm.D. (who serves as President of RSI) and Andrew Fromkin (who serves as the Vant Portfolio Operating Partner for RSI) each currently serve on the board of directors of the Issuer on behalf of the Reporting Person.